Clinical evaluation of cephradine, a new oral cephalosporin.
D000038:Abscess / Q000188:drug therapy; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D001437:Bacteriuria / Q000188:drug therapy; D002481:Cellulitis / Q000188:drug therapy; D002506:Cephalexin / Q000627:therapeutic use; D002511:Cephalosporins / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003510:Cyclohexanes / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D003556:Cystitis / Q000188:drug therapy; D004341:Drug Evaluation; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D006801:Humans; D007711:Klebsiella pneumoniae / Q000187:drug effects; D008199:Lymphadenitis / Q000188:drug therapy; D008205:Lymphangitis / Q000188:drug therapy; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010612:Pharyngitis / Q000188:drug therapy; D012874:Skin Diseases, Infectious / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D013210:Staphylococcus / Q000187:drug effects; D013290:Streptococcal Infections / Q000188:drug therapy; D013297:Streptococcus pyogenes / Q000187:drug effects; D014552:Urinary Tract Infections / Q000188:drug therapy
D002511:Cephalosporins; D003510:Cyclohexanes; D002506:Cephalexin